infliximab (Anbaite / HS626 / HS 626)

Monoclonal antibodies associated IgA nephropathy or other nephropathies.

Miedziaszczyk Miłosz M, Kosiorowski Gracjan G, Kubasik Janusz J, Grabowski Tomasz T et al.

The use of monoclonal antibodies (mAbs) has revolutionized the treatment of autoimmune, inflammatory, and neoplastic diseases. However, accumulating evidence indicates that biologic therapies may be associated with renal adverse events, including various types of glomerulonephritis. The aim of this review was to summarize all reports available in the scientific literature regarding the occurrence of IgA nephropathy after monoclonal antibody treatment. Additionally, the risk of other glomerulonephritis after biologic therapy was discussed. IgA nephropathy (IgAN) is the most commonly reported glomerular lesion associated with monoclonal antibody therapy, particularly with TNF-α inhibitors such as infliximab, adalimumab, golimumab, and etanercept, as well as with immune checkpoint inhibitors targeting the PD-1 (pembrolizumab, nivolumab) and interleukin (ustekinumab) pathways. Proposed mechanisms include immune dysregulation with a shift toward Th2 and Th17-dependent responses, increased production of galactose-deficient IgA1, complement activation, formation of circulating immune complexes, and loss of immune tolerance. In some cases, drug discontinuation and glucocorticoid therapy have resulted in partial or complete disease remission, although progression to end-stage renal disease has also been reported. Due to the potential severity of these complications, initial and periodic monitoring of renal function and urinalysis are recommended in patients receiving monoclonal antibody therapy. Early recognition of renal involvement and prompt treatment modification can improve prognosis.

The right dose for the right patient: Toward precision infliximab therapy in acute severe ulcerative colitis.

Goyal Manjeet K MK, Bishu Shrinivas S

Comparative Efficacy and Safety of Systemic Immunomodulatory Therapies for Non-Infectious Uveitis: A Systematic Review With Pairwise and Network Meta-Analyses.

Chen Kai-Yang KY, Chan Hoi-Chun HC, Chan Chi-Ming CM

Non-infectious uveitis (NIU) is a chronic immune-mediated ocular inflammatory disease that may cause irreversible visual impairment. The comparative efficacy and safety of systemic immunomodulatory therapies, including conventional agents and biologics, remain incompletely defined. This systematic review and network meta-analysis evaluated systemic immunosuppressive therapies for NIU. PubMed/MEDLINE, Cochrane CENTRAL, Scopus and Web of Science Core Collection were searched from inception to May 2, 2026. Randomized controlled trials and prospective comparative cohort studies evaluating systemic immunomodulatory or biologic therapies for NIU were included. The primary efficacy outcome was treatment failure. Safety outcomes included mortality, urinary tract infection, upper respiratory tract infection, injection-site reactions, ocular hypertension, macular edema, and headache. Random-effects pairwise meta-analysis and frequentist network meta-analysis were performed using risk ratios (RRs) with 95% confidence intervals (CIs). Seven studies including 992 participants were included; six were randomized controlled trials and one was a prospective cohort. In the pairwise meta-analysis, adalimumab significantly reduced treatment failure compared with placebo (RR, 0.67; 95% CI, 0.58-0.78; p < 0.0001; I² = 28.1%). The mortality estimate was inconclusive (RR, 3.80; 95% CI, 0.42-34.15), with three deaths in the adalimumab groups and none in the placebo groups. Adalimumab was associated with a higher risk of injection-site reactions than placebo (RR, 2.67; 95% CI, 1.73-4.12). Network meta-analysis showed no significant differences for most safety outcomes, including upper respiratory tract infection, ocular hypertension, macular edema, and headache. Infliximab showed an imprecise urinary tract infection signal versus placebo (RR, 40.98; 95% CI, 1.82-922.17), based on sparse events and one nonrandomized comparison. Adalimumab provides the most consistent evidence for reducing treatment failure in NIU. Comparative safety estimates, particularly for infliximab, remain uncertain and hypothesis-generating. Larger, long-term, head-to-head trials are required.

Severe malnutrition and persistent myopenia despite weight recovery in newly diagnosed stricturing Crohn's disease: A case report.

Costa Beatriz Gabriela da BGD, Nobre Jeniffer Naomy JN, Yoshihara Ryan Nunes Yoshio RNY, Spiller Amanda Luísa AL et al.

Protein-energy malnutrition is a common complication in Crohn's disease (CD). In addition to weight loss, patients may develop significant alterations in body composition, including skeletal muscle depletion, which can negatively affect clinical outcomes and quality of life. Herein, we report on a patient with newly diagnosed CD who presented with severe malnutrition and myopenia, which persisted despite improvements in nutritional intake and body weight. A 27-year-old woman was admitted with abdominal pain, decreased appetite, nausea, vomiting, and progressive weight loss (10 kg, 22% of her usual body weight). Based on clinical presentation, family history, and magnetic resonance enterography findings, stricturing CD was diagnosed. Nutritional assessment revealed severe malnutrition (body weight, 31 kg; body mass index, 12.26 kg/m2; phase angle, 4.4°, intracellular-to-extracellular mass ratio, 0.75). Computed tomography-based body composition analysis demonstrated marked skeletal muscle depletion (skeletal muscle index, 27.5 cm2/m2), confirming myopenia. The patient was treated with corticosteroids, infliximab, azathioprine, and multidisciplinary nutritional management. After 12 months of follow-up, she achieved clinical remission and gained approximately 25% of her initial body weight. Despite significant weight recovery and improved dietary intake, computed tomography (CT) revealed low skeletal muscle mass and increased visceral and subcutaneous adipose tissue, indicating persistent myopenia. This case highlights the importance of comprehensive body composition assessments in CD. Clinical remission and weight gain may not accurately reflect recovery of skeletal muscle mass. Early nutritional evaluation and longitudinal body composition monitoring may be helpful in the management of patients with CD to identify persistent muscle depletion and optimize long-term outcomes.